Dr. Zhenzhen Liu 刘真真
Chief Physician
Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of common benign and malignant breast tumors. Breast-conserving surgery, sentinel lymph node biopsy, and immediate or delayed breast reconstruction after mastectomy.
Dr. Liu is Chief Physician and Director of the Breast Department at Henan Cancer Hospital, holding a medical doctorate. Trained in breast reconstruction using autologous tissue and implants at Oslo University Hospital, Norway (2007–2008). Graduated from Henan Medical University in 1994 with a master’s degree obtained in 2000. Focuses on clinical care and basic research for breast diseases.
Professional roles
- Member, Breast Group, Surgical Branch, Chinese Medical Association
- Member, Breast Group, Oncology Branch, Chinese Medical Association
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Liu Zhenzhen). Papers usually list the name as Zhenzhen Liu or Liu Z.
Selected publications
130 papers on PubMed matched by name and affiliation; 65 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Genet, 2026 (senior author): Clinicopathological characteristics and tumor-detected genetic variations in Chinese patients with ductal carcinoma in situ of the breast. PubMed 42784861
- Nat Commun, 2026 (senior author): Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015). PubMed 42811016
- Breast, 2026 (senior author): Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy. PubMed 42214154
- Ther Adv Med Oncol, 2026 (senior author): (Neo)adjuvant therapy patterns and outcomes in patients with HR+/HER2+ early breast cancer: a real-world study using the national cancer information database in China. PubMed 42369730
- Breast, 2026 (senior author): Global patterns and risk factors of breast cancer in women under 35: a population-based study. PubMed 41946265
- J Immunother Cancer, 2026 (senior author): C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. PubMed 42055709
- Cancer Res Treat, 2025 (senior author): The Application of Contrast-Enhanced Ultrasound Combined with Indocyanine Green Lymphography in the Management of Secondary Upper Limb Lymphedema. PubMed 41265473
- Ther Adv Med Oncol, 2025 (senior author): Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer. PubMed 41229526
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion